Edith Borcoman
Overview
Explore the profile of Edith Borcoman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
793
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Windsor C, Joseph A, Pons S, Mokart D, Pene F, Kouatchet A, et al.
J Intensive Med
. 2025 Jan;
5(1):64-69.
PMID: 39872834
Background: Cancer patients who are exposed to sepsis and had previous chemotherapy may have increased severity. Among chemotherapeutic agents, anthracyclines have been associated with cardiac toxicity. Like other chemotherapeutic agents,...
2.
Frenel J, Mathiot L, Cropet C, Borcoman E, Hervieu A, Coquan E, et al.
J Immunother Cancer
. 2025 Jan;
13(1.
PMID: 39773562
Background: The MOVIE phase I/II trial (NCT03518606) evaluated the safety and antitumor activity of durvalumab and tremelimumab combined with metronomic oral vinorelbine in patients with advanced tumors. We present the...
3.
Loriot Y, Kamal M, Syx L, Nicolle R, Dupain C, Menssouri N, et al.
Nat Commun
. 2024 Oct;
15(1):9370.
PMID: 39478018
No abstract available.
4.
Filippini D, Marret G, Bastien E, Sanchez R, Borcoman E, Le Tourneau C
Chin Clin Oncol
. 2024 Oct;
13(5):73.
PMID: 39390921
Background: The conventional method of drug development in oncology typically progresses through phase I, phase II and randomized phase III trials. Nevertheless, some recent drug approvals for head and neck...
5.
Loriot Y, Kamal M, Syx L, Nicolle R, Dupain C, Menssouri N, et al.
Nat Commun
. 2024 Oct;
15(1):8603.
PMID: 39366934
Metastatic urothelial carcinoma (mUC) is a lethal cancer, with limited therapeutic options. Large-scale studies in early settings provided critical insights into the genomic and transcriptomic characteristics of non-metastatic UC. The...
6.
Bonnin E, Rodrigo Riestra M, Marziali F, Mena Osuna R, Denizeau J, Maurin M, et al.
Nat Commun
. 2024 May;
15(1):3749.
PMID: 38702311
Regulatory T cells (Tregs) are plastic cells playing a pivotal role in the maintenance of immune homeostasis. Tregs actively adapt to the microenvironment where they reside; as a consequence, their...
7.
Dupain C, Gutman T, Girard E, Kamoun C, Marret G, Castel-Ajgal Z, et al.
BMC Biol
. 2024 Feb;
22(1):43.
PMID: 38378561
Background: High tumor mutational burden (TMB) was reported to predict the efficacy of immune checkpoint inhibitors (ICIs). Pembrolizumab, an anti-PD-1, received FDA-approval for the treatment of unresectable/metastatic tumors with high...
8.
Marret G, Temam S, Kamal M, Even C, Delord J, Hoffmann C, et al.
Sci Rep
. 2023 Dec;
13(1):22524.
PMID: 38110561
There is no strong and reliable predictive biomarker in head and neck squamous cell carcinoma (HNSCC) for EGFR inhibitors. We aimed to identify predictive and pharmacodynamic biomarkers of efficacy of...
9.
Bossio S, Abrate C, Tosello Boari J, Rodriguez C, Canale F, Ramello M, et al.
Oncoimmunology
. 2023 Oct;
12(1):2246319.
PMID: 37885970
Conventional CD4 T (Tconv) lymphocytes play important roles in tumor immunity; however, their contribution to tumor elimination remains poorly understood. Here, we describe a subset of tumor-infiltrating Tconv cells characterized...
10.
Martins-Branco D, Nader-Marta G, Gombos A, Barthelemy P, Goncalves A, Borcoman E, et al.
Nat Med
. 2023 Oct;
29(12):2981-2982.
PMID: 37857713
No abstract available.